Acta Med. 2012, 55: 23-26

https://doi.org/10.14712/18059694.2015.70

Expression of Matrix Metalloproteinase 9 in Patients with Oral Lichen Planus

Vladimíra Paulusováa, Jan Lacob, Ivo Dřízhala, Radovan Slezáka

aCharles University in Prague, Faculty of Medicine and University Hospital in Hradec Králové, Czech Republic: Department of Dentistry
bCharles University in Prague, Faculty of Medicine and University Hospital in Hradec Králové, Czech Republic: Fingerland Department of Pathology

Received September 12, 2011
Accepted November 7, 2011

References

1. Piboonniyom SO, Treister N, Pitiphat W, Woo SB. Scoring system for monitoring oral lichenoid lesions: a preliminary study. Oral Surg Oral Med Oral Pathol OralRadiol Endod 2005; 99: 696–703. <https://doi.org/10.1016/j.tripleo.2004.07.013>
2. Wright J. Oral lichen planus. Br Dent J 2004; 197: 224–5. <https://doi.org/10.1038/sj.bdj.4811634>
3. Karatsaidis A, Schreurs O, Helgeland K, Axell T, Schenck K. Erythematous and reticular forms of oral lichen planus and oral lichenoid reactions differ in pathological features related to disease activity. J Oral Pathol Med 2003; 32(5): 275–81. <https://doi.org/10.1034/j.1600-0714.2003.00134.x>
4. Eisen D. Evaluating and treating patients with oral lichen planus. Dermatol Ther 2002; 15: 206–17. <https://doi.org/10.1046/j.1529-8019.2002.01529.x>
5. Dissemond J. Oral lichen planus: an overview. J Dermatol Treat 2004; 15: 136–40. <https://doi.org/10.1080/09546630410030720>
6. Sugerman PB, Savage NW, Zhou XJ, Walsh L, Bigby M. Oral lichen planus. Clin Dermatol 2000; 18: 533–9. <https://doi.org/10.1016/S0738-081X(00)00142-5>
7. Axell T, Rundquist L. Oral lichen planus–a demographic study. Commun Dent Oral Epidemiol 1987; 15: 52–6. <https://doi.org/10.1111/j.1600-0528.1987.tb00480.x>
8. Silverman S Jr, Gorsky M, Lozada‑Nur F. A prospective follow‑up study of 570 patients with oral lichen planus: persistence, remission, and malignant association. Oral Surg Oral Med Oral Pathol 1985; 60: 30–4. <https://doi.org/10.1016/0030-4220(85)90210-5>
9. Eisen D. The clinical features, malignant potential, and systemic associations of oral lichen planus: a study of 723 patients. J Am Acad Dermatol. 2002; 46: 207–14. <https://doi.org/10.1067/mjd.2002.120452>
10. Mollaoglu N. Oral lichen planus: a review. Br J Oral Maxillofac Surg. 2000; 38: 370–7. <https://doi.org/10.1054/bjom.2000.0335>
11. Scully C, Beyli M, Ferreiro MC et al. Update on oral lichen planus: Etiopathogenesis and management. Crit Rev Oral Biol Med 1998; 9: 86–122. <https://doi.org/10.1177/10454411980090010501>
12. Sugerman PB, Savage NW, Walsh LJ et al. The pathogenesis of oral lichen planus. Crit Rev Oral Biol Med 2002; 13: 350–65. <https://doi.org/10.1177/154411130201300405>
13. Roopashree MR, Gondhalekar RV, Shashikanth MC, et al. Pathogenesis of oral lichen planus‑a review. J Oral Pathol Med. 2010; 39: 729–34. <https://doi.org/10.1111/j.1600-0714.2010.00946.x>
14. Sorsa T, Tjäderhane L, Salo T. Matrix metalloproteinases (MMPs) in oral diseases. Oral diseases 2004; 10: 311–318. <https://doi.org/10.1111/j.1601-0825.2004.01038.x>
15. St‑Pierre Y, Themsche CV , Esteve P‑O. Emerging feature in the regulation of MMP‑9 gene expression for the development of novel molecular targets and therapeutic strategies. Curr Drug Targets Inflamm Allergy 2003; 2: 206–15. <https://doi.org/10.2174/1568010033484133>
16. Ram M, Sherer Y, Shoenfeld Y. Matrix metalloproteinase‑9 and autoimune diseases. J Clin Immunol 2006; 26: 299–307. <https://doi.org/10.1007/s10875-006-9022-6>
17. Chakraborti S, Mandal M, Das S, et al. Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem. 2003; 253: 269–85. <https://doi.org/10.1023/A:1026028303196>
18. Giannelli G, Brasssard J, Foti C, et al. Altered expression of basement membrane proteins and their integrin receptors in lichen planus: possible pathogenetic role of gelatinases A and B. Lab Invest 1996, 74: 1091–104.
19. Sutinen M, Kainulainen T, Hurskainen T, et al. Expression of matrix metalloproteinases (MMP‑1 and ‑2) and their inhibitors (TIMP‑1, ‑2 and ‑3) in oral lichen planus, dysplasia, squamous cell carcinoma and lymph node metastasis. Br J Cancer 1998; 77: 2239–45. <https://doi.org/10.1038/bjc.1998.372> <PubMed>
20. Zhou XJ, Sugerman PB, Savage NW, et al. Matrix metalloproteinases and their inhibitors in oral lichen planus. J Cutan Pathol. 2001; 28: 72–82. <https://doi.org/10.1034/j.1600-0560.2001.280203.x>
21. Gunduz K, Demireli P, Inanir I, et al. Expression of matrix metalloproteinases (MMP‑2, MMP‑3, and MMP‑9) and fibronectin in lichen planus. J Cutan Pathol 2006; 33: 545–50. <https://doi.org/10.1111/j.1600-0560.2006.00456.x>
22. Chen Y, Zhang W, Geng N, et al. MMPs, TIMP‑2, and TGF‑beta1 in the cancerization of oral lichen planus. Head Neck. 2008; 30: 1237–45. <https://doi.org/10.1002/hed.20869>
23. Mazzarella N, Femiano F, Gombos F, et al. Matrix metalloproteinase gene expression in oral lichen planus: erosive vs. reticular forms. J Eur Acad Dermatol Venereol. 2006; 20: 953–7.
24. Paulusová V, Rösch C, Dřízhal I, et al. Cytochrome P450 2D6 polymorphism and drug utilization in patients with oral lichen planus. Acta Odontol Scand 2010; 68: 193–8. <https://doi.org/10.3109/00016351003636382>
front cover

ISSN 1211-4286 (Print) ISSN 1805-9694 (Online)

Open access journal

Archive